UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The Securities and Exchange Act of 1934~~the

~~Date~~Securities ofExchange ~~Report~~Act ~~(Date~~ of ~~earliest event reported): February 20, 2019~~1934

~~Protect~~Date ~~Pharmaceuticals~~of ~~Corporation~~Report (Date of earliest event reported): June 1, 2019

~~(Exact~~Protect ~~name~~Pharmaceutical ~~of registrant as specified in its charter)~~Corporation

Nevada		000-54001		27-1877179
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

(Exact Name of Registrant as Specified in Charter)

4876, Cecile Avenue, Las Vegas, NV	89115
Nevada		001-54001	82-4148346
(Address of principal executive offices)	(Zip Code)
(State of incorporation)		(Commission File Number)	(IRS Employer Identification No.)

954-292-0033

4876, Cecile Avenue, Las Vegas NV		89115
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code: (954) 866-3726

~~PROTECT~~Check ~~PHARMACEUTICAL~~the ~~CORPORATION~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~95 Merrick~~[ ~~Way,~~] ~~Third~~Written ~~Floor,~~communications ~~Coral~~pursuant ~~Gables,~~to ~~Florida~~Rule ~~33143~~425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 DFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

~~(Former~~In ~~name~~this orCurrent ~~former~~Report ~~address~~on Form 8-K, if“Company,” ~~changed~~“our ~~since~~company,” ~~last~~“us,” ~~report~~“Protect Pharmaceutical,” and “our” refer to Protect Pharmaceutical Corporation, unless the context requires otherwise.)

~~Check the appropriate box below if the Form 8~~FORWARD-~~K filing is intended to simultaneously satisfy the filing obligation of the registrant~~LOOKING ~~under any of the following provisions (see General Instruction A.2. below):~~STATEMENTS

[Our disclosure ]and ~~Written~~analysis ~~communications~~in ~~pursuant~~this toCurrent ~~Rule~~Report ~~425~~on ~~under~~Form 8-K contains some forward-looking statements. Certain of the ~~Securities~~matters ~~Act~~discussed concerning ~~(17~~our ~~CFR~~operations, ~~230.425)~~cash [flows, ]financial ~~Soliciting~~position, ~~material~~economic ~~pursuant~~performance toand ~~Rule~~financial ~~14a-12~~condition, ~~under~~and the ~~Exchange~~effect ~~Act~~of ~~(17~~economic conditions ~~CFR~~include ~~240.14a~~forward-~~12)~~looking [statements. ]Statements ~~Pre-commencement~~that ~~communications~~are ~~pursuant~~predictive in nature, that depend upon or refer to ~~Rule~~future ~~14d-2(b)~~events or ~~under~~conditions ~~the~~or ~~Exchange~~that ~~Act~~include ~~(17~~words ~~CFR~~such ~~240.14d-2(b))~~as [“expects,” ]“anticipates,” ~~Pre-commencement~~“intends,” ~~communications~~“plans,” “believes,” ~~pursuant~~“estimates” toand ~~Rule~~similar ~~13e~~expressions are forward-~~4(c)~~looking ~~under~~statements. ~~the~~Although ~~Exchange~~we ~~Act~~believe ~~(17~~that these ~~CFR~~statements ~~240~~are based upon reasonable assumptions, including projections of orders, sales, operating margins, earnings, cash flow, research and development costs, working capital, capital expenditures and other projections, they are subject to several risks and uncertainties.~~13e-4(c))~~

~~Indicate~~Investors byare ~~check~~cautioned ~~mark~~that ~~whether~~our ~~the~~forward-looking ~~registrant~~statements isare annot ~~emerging~~guarantees ~~growth~~of ~~company~~future asperformance ~~defined~~and ~~in Rule 405 of~~ the ~~Securities~~actual ~~Act~~results ofor ~~1933 (§230.405~~developments ofmay ~~this~~differ ~~chapter)~~materially orfrom ~~Rule 12b-2 of~~ the ~~Securities~~expectations ~~Exchange~~expressed ~~Act~~in ofthe ~~1934 §240.12b~~forward-2looking ~~of this chapter)~~statements. ~~Emerging growth company [ ]~~

IfAs anfor ~~emerging~~the ~~growth~~forward-looking ~~company~~statements that relate to future financial results and other projections, ~~indicate~~actual byresults ~~check~~will ~~mark~~be ifdifferent due to the ~~registrant~~inherent ~~has~~uncertainty ~~elected~~of ~~not~~estimates, toforecasts ~~use~~and ~~the~~projections ~~extended~~may ~~transition~~be ~~period~~better ~~for~~or worse than projected. Given these uncertainties, ~~complying~~you ~~with~~should not place any ~~new~~reliance oron ~~revised~~these ~~financial~~forward-looking ~~accounting~~statements. ~~standards~~These ~~provided~~forward-looking ~~pursuant~~statements toalso ~~Section~~represent ~~13(~~our estimates and assumptions only as of the date that they were made. We expressly disclaim a) duty to provide updates to these forward-looking statements, and the estimates and assumptions associated with them, after the date of this filing to reflect events or changes in circumstances or changes in expectations or the ~~Exchange~~occurrence ~~Act~~of anticipated events. ~~[ ]~~You are advised, however, to consult any additional disclosures we make in our reports on Form 10-K, Form 10-Q, Form 8-K, or their successors.

~~Item 4.01 Changes in Registrant’s Certifying Accountant~~2

(a)	Termination of Independent Registered Public Accounting Firm
	On December 13, 2018, the Audit Committee of the Board of Directors of PROTECT PHARMACEUTICAL CORPORATION (the “Company”) approved termination of the engagement of Sadler Gibb and Associates, LLC as the Company’s independent registered public accounting firm. On the same day, December 13th 2018, the Company engaged Montgomery Coscia Greilich LLP as the Company’s new independent registered public accounting firm to perform independent audit services for the years ending December 31, 2017 and 2018. Such engagement was approved by the Board of Directors acting as the Audit Committee.
	The Company did not timely file a Form 8-K, Item 4.01 and neither the Company nor the successor auditor notified Sadler Gibb and Associates, LLC of the change of accounting firm at that time. As such, Sadler Gibb and Associates, LLC did not Consent on the inclusion of their report for December 31, 2016 and 2015 in the December 31, 2017 10-K submitted on February 19, 2019. The reports of Sadler on the Company’s consolidated financial statements for the years ended December 31, 2015 and 2016 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the years ended December 31, 2015 and 2016, and through December 13th, 2018, there have been no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with Sadler on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Sadler would have caused Sadler to make reference thereto in its reports on the consolidated financial statements for such years. During the years ended December 31, 2015 and 2016 and from January 1, 2017 through December 13th, 2018, there have been no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).
	The Company provided Sadler with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested that Sadler furnish the Company with a copy of its letter addressed to the Securities and Exchange Commission (the “SEC”), pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not Sadler agrees with the statements related to them made by the Company in this report.
(b)	Newly Engaged Independent Registered Public Accounting Firm
	On December 13th 2018, the Company engaged Montgomery Coscia Greilich LLP as the Company’s new independent registered public accounting firm to perform independent audit services for the years ending December 31, 2017 and 2018. Such engagement was approved by the Board of Directors acting as the Audit Committee.
	During the years ended December 31, 2015 and 2016 and through December 13th 2018, neither the Company, nor anyone on its behalf, consulted Montgomery Coscia Greilich LLP regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, and no written report or oral advice was provided to the Company by Montgomery Coscia Greilich LLP that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors appointed Alan Crooks to fill vacancies on the Company’s Board of Directors, and CEO effective at the close business as of June 12, 2019.

The Board of Directors and the Company’s new officers consist of the following persons are as follows:

Name

Age

Position

Alan Crooks

222 S. Main St. #500

Salt Lake City, UT 84101

Director

The directors will serve until the next annual meeting of stockholders of the Company and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal. The following is information concerning the business backgrounds of Alan Crooks.

Alan Crooks. A National and international recognized political and business consultant. Has been a key individual with the startup and expansion of several businesses internationally. His expertise in the political arena have been invaluable to the business he has helped.

Effective June 12, 2019, Una Taylor resigned as an officer of Protect Pharmaceutical Corporation and of the Board of Directors. There were no disagreements with these former directors of the Company as to its operations, policies or practices.

The Board of Directors will not adopt a procedure for stockholders to send communications to the Board of Directors until it has considered and reviewed the merits of several possible alternative communications procedures. The Company has no policy and does not presently intend to consider director candidates for election to the Board of Directors recommended by security holders, although that policy may be reconsidered in the future.

ITEM 7.01 REGULATION FD DISCLOSURE.

Note: the information in this report (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed a determination or an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits

Exhibit No.		Description
Ex 1		Resignation Letter

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Protect Pharmaceutical Corporation.
June 11, 2019
Date: February 20, 2019		By:	/s/ Una Taylor
	Protect Pharmaceutical Corporation
			Una Taylor
	By:	/s/ Una Taylor
			Chief Executive Officer
		Una Taylor, President

Filing Compare · PROTECT PHARMACEUTICAL Corp